Article
Pharmacology & Pharmacy
Shailly Mehrotra, Atul Bhattaram, Kevin Krudys, Michael Bewernitz, Ramana Uppoor, Mehul Mehta, Tao Liu, Philip Sheridan, Norman Hershkowitz, Nicholas Kozauer, Eric Bastings, Billy Dunn, Angela Yuxin Men
Summary: The US FDA has concluded that drugs approved for treating partial onset seizures in adults can be applied to pediatric patients aged one month and older, eliminating the need for independent efficacy trials. This study analyzes dosing, pharmacokinetic, exposure-response, and clinical data from eight approved drugs to support the extrapolation of efficacy in pediatric patients with partial onset seizures. The results show that based on disease similarity, response to treatment, and exposure-response relationships, the extrapolation of efficacy in pediatric patients aged one month and above is justified.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Clinical Neurology
Paolo Bonanni, Antonio Gambardella, Paolo Tinuper, Benedetto Acone, Emilio Perucca, Giangennaro Coppola
Summary: Consensus was reached on the suitability of Perampanel as a first add-on based on its positive impact on quality of life, efficacy, tolerability, ease of use, and unique mechanism of action. However, potential unfavorable factors include slow dose titration, behavioral adverse effects, lack of safety information during pregnancy, and limited access to plasma Perampanel levels.
Article
Behavioral Sciences
Naoya Hasegawa, Jun Tohyama
Summary: The study evaluated irritability as a side effect in epilepsy patients receiving both levetiracetam (LEV) and perampanel (PER) therapy, finding that LEV and PER caused irritability in different patient groups. Irritability was associated with EEG findings of temporal focal epileptic discharge and higher dosages of LEV for LEV-related irritability, as well as with psychiatric comorbidity of irritability and EEG findings of nontemporal focal epileptic discharge for PER-related irritability.
EPILEPSY & BEHAVIOR
(2021)
Article
Clinical Neurology
Colin B. Josephson, Samuel Wiebe, Guillermo Delgado-Garcia, Arturo Gonzalez-Izquierdo, Spiros Denaxas, Tolulope T. Sajobi, Mubasiru Lamidi, Meng Wang, Mark R. Keezer
Summary: This study revealed a dose-dependent hazard of incident cardiovascular disease associated with enzyme-inducing antiseizure medications (eiASMs). The hazard of incident cardiovascular disease is higher in those receiving eiASMs, and the risk seems to reach clinical significance by approximately 10 years from first exposure. The association between eiASMs and cardiovascular disease risk is dose-dependent and can be significant after long-term use.
Article
Clinical Neurology
Elinor Lee-Lane, Fatemeh Torabi, Arron Lacey, Beata Fonferko-Shadrach, Daniel Harris, Ashley Akbari, Ronan A. Lyons, Mark Rees, Inder Sawhney, Julian Halcox, Rob Powell, William Owen Pickrell
Summary: This study investigated the association between epilepsy, antiepileptic drugs, and major cardiovascular events using population-level data. The results indicated that individuals with epilepsy prescribed antiepileptic drugs are at an increased risk of experiencing major cardiovascular events, highlighting the importance of cardiovascular risk management in epilepsy care.
Article
Chemistry, Analytical
Bruno Charlier, Albino Coglianese, Francesca Felicia Operto, Federica De Rosa, Francesca Mensitieri, Giangennaro Coppola, Amelia Filippelli, Fabrizio Dal Piaz, Viviana Izzo
Summary: Therapeutic drug monitoring is crucial for improving the quality of antiepileptic drug use, especially in specific clinical situations. A novel method for measuring perampanel concentration in plasma samples was developed and compared with a commercially available method, showing the potential for clinical routine use as an alternative to LC-MS/MS.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
(2021)
Editorial Material
Clinical Neurology
Wyatt P. Bensken, Ivan Sanchez Fernandez
Summary: One in four people in the United States who take prescription drugs face difficulties affording them, including patients with epilepsy. Health plans often restrict coverage for newer antiseizure medications, leading to delays in treatment. Neurologists can address this issue by understanding the causes and finding actionable solutions.
Article
Biochemistry & Molecular Biology
Marta Andres-Mach, Aleksandra Szewczyk, Miroslaw Zagaja, Joanna Szala-Rycaj, Marta Kinga Lemieszek, Maciej Maj, Michal Abram, Krzysztof Kaminski
Summary: The study discovered that the new compound C11 has a protective effect on astrocytes in vitro and beneficial effects on neurogenesis and cognitive functions in vivo, indicating the need for further research on its neuroprotective mechanisms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Clinical Neurology
Alekhya Lavu, Laila Aboulatta, Ahmed M. Abou-Setta, Basma Aloud, Nicole Askin, Rasheda Rabbani, Walid Shouman, Ryan Zarychanski, Sherif Eltonsy
Summary: This systematic review examines the effectiveness and safety of Perampanel in treating epilepsy. The results show a significant reduction in seizures and a potential increase in discontinuations due to treatment-emergent adverse events (TEAEs). The most commonly reported TEAEs are non-threatening, but there is a possibility of rare but serious adverse psychological outcomes.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
(2022)
Review
Behavioral Sciences
Jose Carlos Estevez-Maria, Inigo Garamendi-Ruiz
Summary: This study aims to evaluate the efficacy and safety of perampanel in clinical practice in Europe. The results show that perampanel can effectively reduce seizures in some patients and is safe and reliable in clinical practice, although the incidence of adverse events is higher.
EPILEPSY & BEHAVIOR
(2022)
Article
Clinical Neurology
Edward Faught, Xuan Li, Jiyoon Choi, Manoj Malhotra, Russell L. Knoth
Summary: The study evaluated the risk of hospitalization following perampanel initiation and found a significant reduction in hospitalization rates over one year. Perampanel showed better hospitalization rates compared to lacosamide.
Review
Clinical Neurology
Roberta Roberti, Carmen De Caro, Luigi Francesco Iannone, Gaetano Zaccara, Simona Lattanzi, Emilio Russo
Summary: Cenobamate is a promising antiseizure medication for focal onset seizures in adults, with a unique mechanism of action and pharmacokinetic profile. Further clinical studies are needed to fully understand its clinical characteristics and potential interactions with other drugs.
Article
Behavioral Sciences
Omar A. Danoun, Andrew Zillgitt, Chloe Hill, Deepti Zutshi, David Harris, Gamaleldin Osman, Rohit Marawar, Subhendu Rath, Maryam J. Syed, Muhammad Affan, Lonni Schultz, Vibhangini S. Wasade
Summary: This study compared healthcare resource utilization among recipients of PER-based combinations versus recipients of other non-PER-based combinations. Results showed that patients treated with PER-based combinations had fewer all-cause and epilepsy-related hospitalizations, and fewer all-cause clinic/office/outpatient visits compared with patients treated with most other non-PER-based combinations.
EPILEPSY & BEHAVIOR
(2021)
Article
Biochemical Research Methods
Rosa Sabenca, Joana Bicker, Rui Silva, Andreia Carona, Ana Silva, Isabel Santana, Francisco Sales, Amilcar Falcao, Ana Fortuna
Summary: This study describes the development and validation of a bioanalytical technique for the simultaneous quantification of perampanel and lamotrigine in human plasma samples using HPLC-DAD, with a linear calibration curve, good precision, and accuracy. The method was successfully applied to drug-resistant epileptic patients and can be used for therapeutic drug monitoring and drug-drug interaction assessment.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
(2021)
Review
Clinical Neurology
Ashley Reynolds, Michaela Vranic-Peters, Alan Lai, David B. Grayden, Mark J. Cook, Andre Peterson
Summary: This scoping review explores prognostic electroencephalographic (EEG) biomarkers and models for assessing antiseizure medication (ASM) efficacy in epilepsy treatment. Qualitative and quantitative biomarkers, as well as prognostic models using EEG features, are identified, but further research is needed to determine their clinical application.
Article
Clinical Neurology
Blanca Vazquez, Haichen Yang, Betsy Williams, Sharon Zhou, Antonio Laurenza
Article
Clinical Neurology
William Rosenfeld, Joan Conry, Lieven Lagae, Guntis Rozentals, Haichen Yang, Randi Fain, Betsy Williams, Dinesh Kumar, Jin Zhu, Antonio Laurenza
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
(2015)
Article
Clinical Neurology
Ilo E. Leppik, Haichen Yang, Betsy Williams, Sharon Zhou, Randi Fain, Anna Patten, Francesco Bibbiani, Antonio Laurenza
Article
Clinical Neurology
Alexis Arzimanoglou, Jose A. Ferreira, Andrew Satlin, Shannon Mendes, Betsy Williams, David Critchley, Edgar Schuck, Ziad Hussein, Dinesh Kumar, Shobha Dhadda, Francesco Bibbiani
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
(2016)
Article
Behavioral Sciences
Steve Chung, Betsy Williams, Cindy Dobrinsky, Anna Patten, Haichen Yang, Antonio Laurenza
EPILEPSY & BEHAVIOR
(2017)
Article
Clinical Neurology
Sanjeev Kothare, Gerhard Kluger, Rajesh Sachdeo, Betsy Williams, Omar Olhaye, Carlos Perdomo, Francesco Bibbiani
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
(2017)
Article
Clinical Neurology
Gregory L. Krauss, Emilio Perucca, Patrick Kwan, Elinor Ben-Menachem, Xue-Feng Wang, Jerry J. Shih, Anna Patten, Haichen Yang, Betsy Williams, Antonio Laurenza
Article
Behavioral Sciences
Jesus E. Pina-Garza, Lieven Lagae, Vicente Villanueva, J. Ben Renfroe, Antonio Laurenza, Betsy Williams, Dinesh Kumar, Kimford J. Meador
EPILEPSY & BEHAVIOR
(2018)
Article
Clinical Neurology
Bernhard J. Steinhoff, Anna Patten, Betsy Williams, Manoj Malhotra
Article
Behavioral Sciences
J. Eric Pina-Garza, William Rosenfeld, Kazunori Saeki, Vicente Villanueva, Harumi Yoshinaga, Anna Patten, Betsy Williams, Manoj Malhotra
EPILEPSY & BEHAVIOR
(2020)
Article
Clinical Neurology
Ivan Rektor, Gregory L. Krauss, Yushi Inoue, Sunao Kaneko, Betsy Williams, Anna Patten, Manoj Malhotra, Antonio Laurenza, Robert T. Wechsler
Article
Behavioral Sciences
Betsy Williams, Barry E. Gidal, Trevor Resnick, John Baker, Matthew Holtzman, Nicole Sparling, Joshua Maher, Craig Plauschinat
Summary: Healthcare providers in the US consider titration schedules important in ASM treatment decision-making, preferring shorter and simpler schedules for better treatment outcomes. There is a discrepancy between providers' and patients' understanding of and adherence to titration schedules.
EPILEPSY & BEHAVIOR
(2021)
Article
Clinical Neurology
Gregory L. Krauss, Elinor Ben-Menachem, Robert T. Wechsler, Anna Patten, Betsy Williams, Antonio Laurenza, Manoj Malhotra
Summary: This study identified potential predictive factors for patients with focal-onset seizures achieving a major treatment response by analyzing clinical trial data. These factors may help guide clinicians in predicting patient responses to treatment and optimizing individual treatment regimens.
Article
Clinical Neurology
Stephane Auvin, Betsy Williams, Rob McMurray, Dinesh Kumar, Carlos Perdomo, Manoj Malhotra